

# Marios Politis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1691722/publications.pdf>

Version: 2024-02-01

127  
papers

8,968  
citations

44069

48  
h-index

45317

90  
g-index

130  
all docs

130  
docs citations

130  
times ranked

10430  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.   | 10.1 | 705       |
| 2  | Parkinson's disease symptoms: The patient's perspective. <i>Movement Disorders</i> , 2010, 25, 1646-1651.  | 3.9  | 464       |
| 3  | Clinical application of stem cell therapy in Parkinson's disease. <i>BMC Medicine</i> , 2012, 10, 1.   | 5.5  | 285       |
| 4  | Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. <i>Brain</i> , 2011, 134, 969-978.  | 7.6  | 283       |
| 5  | Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants. <i>Science Translational Medicine</i> , 2010, 2, 38ra46.                             | 12.4 | 272       |
| 6  | Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 83.  | 9.0  | 257       |
| 7  | The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.  | 10.1 | 252       |
| 8  | Serotonin in Parkinson's disease. <i>Behavioural Brain Research</i> , 2015, 277, 136-145.  | 2.2  | 224       |
| 9  | Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , 2010, 40, 216-221.   | 4.4  | 213       |
| 10 | Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. <i>Journal of Clinical Investigation</i> , 2014, 124, 1340-1349.                     | 8.2  | 202       |
| 11 | Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. <i>Journal of Neurology</i> , 2019, 266, 1293-1302.   | 3.6  | 196       |
| 12 | Neuroimaging in Parkinson disease: from research setting to clinical practice. <i>Nature Reviews Neurology</i> , 2014, 10, 708-722.  | 10.1 | 195       |
| 13 | Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. <i>Human Brain Mapping</i> , 2011, 32, 258-270. | 3.6  | 181       |
| 14 | Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. <i>Brain</i> , 2013, 136, 400-411.   | 7.6  | 172       |
| 15 | Diabetes mellitus and Parkinson disease. <i>Neurology</i> , 2018, 90, e1654-e1662.   | 1.1  | 158       |
| 16 | Hypothalamic involvement in Huntington's disease: an in vivo PET study. <i>Brain</i> , 2008, 131, 2860-2869.   | 7.6  | 155       |
| 17 | Craft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. <i>Movement Disorders</i> , 2011, 26, 1997-2003.                                     | 3.9  | 151       |
| 18 | Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. <i>Neurology</i> , 2012, 79, 523-530.  | 1.1  | 150       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. <i>Brain</i> , 2018, 141, 1501-1516.  | 7.6  | 148       |
| 20 | Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , 2015, 83, 115-121.  | 4.4  | 133       |
| 21 | Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. <i>Aids</i> , 2014, 28, 67-72.  | 2.2  | 128       |
| 22 | Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 5424-5442.  | 3.6  | 127       |
| 23 | Advances in MRI Methodology. <i>International Review of Neurobiology</i> , 2018, 141, 31-76.   | 2.0  | 124       |
| 24 | REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. <i>Neurology</i> , 2018, 91, e894-e905.   | 1.1  | 112       |
| 25 | Imaging in Parkinson's disease. <i>Clinical Medicine</i> , 2016, 16, 371-375.  | 1.9  | 110       |
| 26 | Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts. <i>Science Translational Medicine</i> , 2012, 4, 128ra41.   | 12.4 | 107       |
| 27 | Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. <i>Experimental Neurology</i> , 2008, 214, 112-116.  | 4.1  | 101       |
| 28 | Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , 2015, 138, 3003-3015.  | 7.6  | 100       |
| 29 | Imaging of microglia in patients with neurodegenerative disorders. <i>Frontiers in Pharmacology</i> , 2012, 3, 96.   | 3.5  | 98        |
| 30 | Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. <i>Neurology</i> , 2013, 80, 1850-1855.   | 1.1  | 95        |
| 31 | Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80. | 10.2 | 94        |
| 32 | Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. <i>Brain</i> , 2015, 138, 3016-3029.  | 7.6  | 90        |
| 33 | Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017, 32, 181-192.   | 3.9  | 88        |
| 34 | Cholinergic imaging in dementia spectrum disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1376-1386.   | 6.4  | 87        |
| 35 | Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. <i>Annals of Neurology</i> , 2017, 81, 171-180.   | 5.3  | 77        |
| 36 | Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. <i>Scientific World Journal</i> , The, 2011, 11, 1726-1734.   | 2.1  | 76        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. <i>Brain</i> , 2015, 138, 110-119.  | 7.6  | 76        |
| 38 | Positron emission tomography imaging in neurological disorders. <i>Journal of Neurology</i> , 2012, 259, 1769-1780.   | 3.6  | 75        |
| 39 | Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo <sup>11</sup> C-BU99008 PET study. <i>Brain</i> , 2019, 142, 3116-3128.                               | 7.6  | 73        |
| 40 | Serotonin-to-dopamine transporter ratios in Parkinson disease. <i>Neurology</i> , 2016, 86, 1152-1158.  | 1.1  | 71        |
| 41 | Serotonergic pathology and disease burden in the premotor and motor phase of A53T $\alpha$ -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.      | 10.2 | 70        |
| 42 | Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study. <i>Neurobiology of Disease</i> , 2014, 65, 203-210. | 4.4  | 66        |
| 43 | Current status of PET imaging in Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1171-1182.   | 6.4  | 66        |
| 44 | Neuroimaging in Huntington's disease. <i>World Journal of Radiology</i> , 2014, 6, 301.   | 1.1  | 60        |
| 45 | Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , 2010, 37, 356-361.  | 4.4  | 56        |
| 46 | The catechol-O-methyltransferase Val158Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. <i>Brain</i> , 2012, 135, 2449-2457.                 | 7.6  | 56        |
| 47 | Parkinson's Disease, Diabetes and Cognitive Impairment. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2016, 10, 11-21.  | 0.6  | 52        |
| 48 | Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 18, 630-637.   | 2.7  | 52        |
| 49 | Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2018, 387, 220-227.                                     | 0.6  | 51        |
| 50 | Cortical thinning across Parkinson's disease stages and clinical correlates. <i>Journal of the Neurological Sciences</i> , 2019, 398, 31-38.  | 0.6  | 51        |
| 51 | Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. <i>Movement Disorders</i> , 2016, 31, 1020-1026.   | 3.9  | 49        |
| 52 | Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle $\alpha$ in Early Drug-Naive Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1416-1427.   | 3.9  | 48        |
| 53 | Positron emission tomography neuroimaging in Parkinson's disease. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 323-41.   | 0.0  | 48        |
| 54 | Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?. <i>BMC Medicine</i> , 2010, 8, 80.  | 5.5  | 46        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Dopamine receptor mapping with PET imaging in Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 2251-2263.  | 3.6 | 45        |
| 56 | <sup>11</sup> C-PE2I and <sup>18</sup> F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. <i>Movement Disorders</i> , 2018, 33, 117-127.   | 3.9 | 45        |
| 57 | Neuroimaging in Lewy body dementia. <i>Journal of Neurology</i> , 2019, 266, 1-26.  | 3.6 | 45        |
| 58 | Molecular Imaging Markers to Track Huntington's Disease Pathology. <i>Frontiers in Neurology</i> , 2017, 8, 11.   | 2.4 | 44        |
| 59 | The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. <i>Neurobiology of Aging</i> , 2015, 36, 1736-1742.  | 3.1 | 42        |
| 60 | Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. <i>Journal of Neurology</i> , 2015, 262, 2653-2661.   | 3.6 | 41        |
| 61 | Single versus multiple impulse control disorders in Parkinson's disease: an <sup>11</sup> C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. <i>Journal of Neurology</i> , 2015, 262, 1504-1514. | 3.6 | 41        |
| 62 | Serotonergic mediated body mass index changes in Parkinson's disease. <i>Neurobiology of Disease</i> , 2011, 43, 609-615.   | 4.4 | 40        |
| 63 | Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum. <i>Neurobiology of Aging</i> , 2021, 97, 1-9.  | 3.1 | 40        |
| 64 | PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> , 2018, 33, 1961-1965.  | 3.9 | 38        |
| 65 | Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016, 368, 243-248.  | 0.6 | 37        |
| 66 | A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2244-2254.   | 6.4 | 37        |
| 67 | Ambient particulate matter and its potential neurological consequences. <i>Reviews in the Neurosciences</i> , 2013, 24, 323-35.   | 2.9 | 36        |
| 68 | Recent imaging advances in neurology. <i>Journal of Neurology</i> , 2015, 262, 2182-2194.   | 3.6 | 33        |
| 69 | Phosphodiesterase 10A in Schizophrenia: A PET Study Using [ <sup>11</sup> C]IMA107. <i>American Journal of Psychiatry</i> , 2016, 173, 714-721.   | 7.2 | 33        |
| 70 | Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients. <i>NeuroImage: Clinical</i> , 2017, 16, 455-460.  | 2.7 | 33        |
| 71 | Dementia spectrum disorders: lessons learnt from decades with PET research. <i>Journal of Neural Transmission</i> , 2019, 126, 233-251.   | 2.8 | 32        |
| 72 | Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation. <i>PLoS ONE</i> , 2012, 7, e38980.  | 2.5 | 30        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Loss of phosphodiesterase 4 in Parkinson disease. <i>Neurology</i> , 2017, 89, 586-593.   | 1.1 | 30        |
| 74 | Be vigilant for dementia in Parkinson's disease. <i>Practitioner</i> , 2017, 261, 11-5.   | 0.3 | 27        |
| 75 | The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. <i>Journal of Neural Transmission</i> , 2018, 125, 1217-1223.   | 2.8 | 26        |
| 76 | Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.  | 6.4 | 26        |
| 77 | Speech difficulties in early de novo patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 256-261.  | 2.2 | 26        |
| 78 | Dopamine reuptake transporter's single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 478-482.      | 3.9 | 25        |
| 79 | Cerebral serotonin transporter measurements with [ <sup>11</sup> C]DASB: A review on acquisition and preprocessing across 21 PET centres. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 210-222. | 4.3 | 25        |
| 80 | Reduplicative Paramnesia: A Review. <i>Psychopathology</i> , 2012, 45, 337-343.   | 1.5 | 24        |
| 81 | Molecular Imaging of the Serotonergic System in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 173-210.  | 2.0 | 24        |
| 82 | Imaging Markers of Progression in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 586-596.  | 1.5 | 23        |
| 83 | Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.   | 3.7 | 23        |
| 84 | Imaging in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 233-274.   | 2.0 | 21        |
| 85 | PET in Multiple Sclerosis. <i>Clinical Nuclear Medicine</i> , 2015, 40, e46-e52.  | 1.3 | 20        |
| 86 | PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 90.  | 4.2 | 20        |
| 87 | Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 2581.   | 4.1 | 20        |
| 88 | Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. <i>Journal of Neurology</i> , 2020, 267, 2042-2053.  | 3.6 | 20        |
| 89 | Brain imaging after neural transplantation. <i>Progress in Brain Research</i> , 2010, 184, 193-203.   | 1.4 | 19        |
| 90 | [ <sup>18</sup> F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 366-378.                                  | 6.4 | 19        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Molecular imaging of levodopa-induced dyskinesias. Cellular and Molecular Life Sciences, 2015, 72, 2107-2117.  | 5.4 | 18        |
| 92  | Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders, 2017, 32, 235-240.   | 3.9 | 18        |
| 93  | Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 185-196.                      | 1.9 | 18        |
| 94  | Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 131-172.  | 2.0 | 18        |
| 95  | Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 541-560.                 | 2.6 | 18        |
| 96  | In vivo imaging of the integration and function of nigral grafts in clinical trials. Progress in Brain Research, 2012, 200, 199-220.   | 1.4 | 16        |
| 97  | Neuroimaging of Sleep Disturbances in Movement Disorders. Frontiers in Neurology, 2018, 9, 767.  | 2.4 | 15        |
| 98  | Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209. | 2.2 | 15        |
| 99  | Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. Movement Disorders, 2019, 34, 1505-1515.                              | 3.9 | 15        |
| 100 | Imaging the Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 179-257.  | 2.0 | 14        |
| 101 | Structural Magnetic Resonance Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 335-380.   | 2.0 | 14        |
| 102 | Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). Journal of Neurology, 2019, 266, 1203-1210.   | 3.6 | 14        |
| 103 | Hybrid PET-MRI Applications in Movement Disorders. International Review of Neurobiology, 2019, 144, 211-257.   | 2.0 | 14        |
| 104 | Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC Medicine, 2011, 9, 50.   | 5.5 | 13        |
| 105 | Problematic Internet use in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 482-487.  | 2.2 | 13        |
| 106 | Predictors of RBD progression and conversion to synucleinopathies. Current Neurology and Neuroscience Reports, 2022, 22, 93-104.   | 4.2 | 13        |
| 107 | Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. Sleep Medicine, 2018, 43, 25-30.  | 1.6 | 12        |
| 108 | Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson's disease patients. PLoS ONE, 2019, 14, e0214352.               | 2.5 | 12        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 189-205.                            | 1.8  | 12        |
| 110 | The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 77, 163-169.  | 2.2  | 11        |
| 111 | Serotonergic imaging in Parkinson's disease. Progress in Brain Research, 2021, 261, 303-338.  | 1.4  | 11        |
| 112 | Molecular Imaging of Dementia With Lewy Bodies. International Review of Neurobiology, 2019, 144, 59-93.   | 2.0  | 10        |
| 113 | Clinical utility of DaTscan&trade; (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. Degenerative Neurological and Neuromuscular Disease, 2013, 3, 33.                                       | 1.3  | 9         |
| 114 | Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism and Related Disorders, 2015, 21, 1336-1341.  | 2.2  | 9         |
| 115 | Serotonergic loss underlying apathy in Parkinson's disease. Brain, 2016, 139, 2338-2339.  | 7.6  | 9         |
| 116 | Urinary dysfunction in early de novo patients with Parkinson's disease. Movement Disorders, 2017, 32, 939-940.  | 3.9  | 9         |
| 117 | Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. BMC Neuroscience, 2019, 20, 55.  | 1.9  | 9         |
| 118 | Imaging Transplantation in Movement Disorders. International Review of Neurobiology, 2018, 143, 213-263.  | 2.0  | 6         |
| 119 | Molecular Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 289-333.  | 2.0  | 6         |
| 120 | Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). Journal of Neural Transmission, 2020, 127, 51-59.   | 2.8  | 6         |
| 121 | Impulse Control Disorders in Parkinson's Disease: A Review. Current Psychiatry Reviews, 2012, 8, 235-246.   | 0.9  | 1         |
| 122 | The X-Linked Hypothesis of Brain Disorders. Neuroscientist, 2015, 21, 589-598.  | 3.5  | 1         |
| 123 | Disease progression in LRRK2 parkinsonism. Lancet Neurology, The, 2017, 16, 334-335.  | 10.2 | 1         |
| 124 | Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases. Stem Cells, 2022, 40, 724-735.  | 3.2  | 1         |
| 125 | SEROTONIN-TO-DOPAMINE TRANSPORTER RATIOS IN THE STRIATUM OF PATIENTS WITH PARKINSON'S DISEASE: IMPACT ON LEVODOPA-INDUCED DYSKINESIAS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.96-e4.     | 1.9  | 0         |
| 126 | A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016). European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 548-550. | 6.4  | 0         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Imaging in Huntingtonâ€™s. Neuromethods, 2022, , 457-505. | 0.3 | 0         |